Confessions from a Retired Addiction Treatment CEO: The Industry Keeps ‘Recycling Solutions’
Impact on your practice
This opinion piece reflects systemic challenges in addiction treatment funding and positioning that affect all providers. While not a policy change, it highlights structural barriers therapists face: inconsistent funding streams, stigma, and fragmented systems. Understanding these dynamics helps therapists advocate for policy reform and navigate the current landscape.
Key facts
Retired CEO of large nonprofit treatment system warns industry 'recycles solutions' and stymies progress
Persistent challenges include volatile funding, criminal justice vs. healthcare framing, and ongoing stigma
SUD and behavioral health remain siloed despite integration efforts
Funding for treatment historically tied to law enforcement rather than healthcare systems
Therapy Companion analysis
This opinion piece exposes structural vulnerabilities in addiction treatment funding that directly affect your reimbursement and operational sustainability. The retired CEO's core observation—that addiction treatment remains partially tethered to criminal justice funding rather than fully integrated into healthcare systems—means your practice likely experiences fragmented payment streams, inconsistent insurance coverage, and higher administrative burden than comparable medical specialties. If you bill Medicaid for substance use disorder (SUD) treatment, you're operating in a system where state agencies may lack accurate admission and readmission data, making it harder for policymakers to advocate for adequate reimbursement rates. The siloing of SUD and behavioral health services also affects your scope: if you're an LCSW, LPC, or MFT treating co-occurring disorders, you may face separate authorization requirements, different documentation standards, and payment denials when treating the same patient across diagnostic categories. The CEO's warning about insurance companies micromanaging benefits without clear provider contracts suggests you should audit your current insurance agreements—many likely lack explicit performance expectations, leaving you vulnerable to retroactive denials or rate cuts. The data transparency gap the CEO identifies is particularly damaging: insurance companies hold longitudinal outcome data on your patients that could justify higher reimbursement or expanded services, but they're not sharing it with you or state regulators, leaving your practice unable to demonstrate clinical value or advocate for policy changes based on evidence.
Background
Addiction treatment has historically occupied an awkward institutional space between criminal justice and healthcare. For decades, federal funding flowed through law enforcement channels, and treatment was framed as crime reduction rather than disease management. The Affordable Care Act and Medicaid expansion theoretically shifted this by mandating substance use disorder coverage, but the infrastructure never fully transitioned. Today, treatment organizations still operate with volatile funding dependent on grant cycles, criminal justice referrals, and insurance contracts that are often poorly defined. Meanwhile, behavioral health and SUD services remain administratively separate in most insurance and state systems, despite clinical evidence that they should be integrated. This fragmentation creates perverse incentives: providers compete for limited funding, insurance companies lack incentive to share data that would improve outcomes, and state governments can't accurately assess treatment needs or outcomes. The CEO's 50-year perspective reveals that despite repeated cycles of 'reform' and consultant-driven initiatives, these fundamental structural problems persist because they're embedded in how funding flows and how different sectors (criminal justice, insurance, healthcare) maintain separate fiefdoms.
What you should do
Audit your current insurance contracts for SUD and behavioral health services. Document whether each contract specifies: (1) authorization criteria, (2) documentation requirements, (3) payment rates, and (4) appeal procedures. If contracts are vague or reference 'standard industry practices' without definition, request written clarification from each insurer before year-end. This protects you from retroactive denials.
If you treat co-occurring SUD and mental health disorders, map your current billing practices across diagnostic categories. Identify whether you're billing separately for SUD vs. behavioral health sessions and whether you're experiencing differential denial rates. Prepare a summary for your state's insurance commissioner if you observe systematic underpayment for SUD-coded services compared to mental health-only services.
Join or engage with your state's addiction treatment trade association. The CEO emphasizes that associations with legislative relationships are the primary vehicle for policy change. Specifically, advocate for state-level data transparency mandates requiring insurers to report admission and readmission rates to state health departments—this data would strengthen your practice's ability to justify expanded services and higher reimbursement.
Document your practice's experience with fragmented authorization and payment across SUD and behavioral health. Track: (1) number of prior authorization requests by diagnosis, (2) denial rates, (3) time spent on appeals, and (4) revenue impact. Share this data with your state licensing board and insurance commissioner as evidence of system dysfunction affecting patient access.
Review whether your practice is positioned to capture Medicaid managed care contracts. The CEO notes that state Medicaid managed care organizations have data-sharing obligations that commercial insurers lack. If you're not contracted with your state's Medicaid MCOs, this may be a revenue opportunity, but only if you negotiate explicit performance metrics and data access rights into the contract.
Notable excerpts
"The whole disease was dealt with from the criminal justice point of view, and it remained that a lot of funding for treatment came from the law enforcement side of the business... we still have stigma. We still have the discrimination." — Retired addiction treatment CEO, highlighting the persistent criminal justice framing that undermines healthcare-based reimbursement.
"The insurance company needs to be able to focus on that data set, work with the providers and develop information transfers that really help both the provider and the insurance company to be able to deal with this population." — Retired CEO, identifying the data transparency gap that prevents providers from demonstrating outcomes and advocating for adequate payment.
Policy changes drive denial patterns
Therapy Companion tracks both: the policy shifts on this page and the denial patterns hitting your claims.
Related policy changes
[MA] H4895: Expanding access to mental health services
This bill aims to expand mental health service access in Massachusetts and has cleared committee with a favorable recommendation. Depending on final language, it could affect reimbursement rates, telehealth authorization, or insurance coverage requirements.
[TN] SB1248: AN ACT to amend Tennessee Code Annotated, Title 4; Title 8; Title 33; Title 39; Title 49; Title 53; Title 56; Title 63; Title 68 and Title 71, relative to mental health.
This comprehensive TN mental health bill touches multiple code sections and could affect licensure, scope of practice, insurance requirements, and workforce regulations. Therapists should monitor its progress closely as it moves through committee.
Advancing the Future of Behavioral Health Data Exchange
This policy direction addresses a critical pain point for therapists: the lack of integrated health data exchange with primary care and medical providers. Improved interoperability could reduce documentation burden, improve care coordination, and reduce liability from medication interactions or missed diagnoses. However, it may also increase compliance requirements and data security obligations.
Opinion: MAHA is rewriting the vocabulary of American mental health care
Federal deprescribing initiatives create new clinical and billing opportunities for therapists while potentially pressuring prescribing practices. Therapists should understand the evidence, reimbursement rules, and ethical considerations around medication tapering to protect clients and navigate changing clinical norms.